logo

IMRX

Immuneering·NASDAQ
--
--(--)
--
--(--)

IMRX fundamentals

Immuneering (IMRX) released its earnings on Nov 12, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.38 (YoY +22.45%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.38
+22.45%
Report date
Nov 12, 2025
IMRX Earnings Call Summary for Q3,2025
  • Breakthrough Pancreatic Cancer Data: 86% overall survival at nine months vs. 47% standard care, with complete responses in FOLFIRINOX combo arm.
  • $227M Cash Runway: 2029 funding secured for phase 3 trial and lung cancer collaborations.
  • Unique Mechanism: Deep cyclic MEK inhibition blocks resistance, no MAPK pathway mutations detected.
  • Upcoming Trials: Phase 3 pancreatic cancer start mid-2026; Libtayo lung trial H2 2026; Lilly KRAS G12C combo pending.
EPS
Revenue

Revenue & Expenses

Key Indicators

Immuneering (IMRX) key financial stats and ratios, covering profitability, financial health, and leverage.
Immuneering (IMRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Immuneering (IMRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Immuneering (IMRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Immuneering (IMRX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Immuneering (IMRX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield